Comparative Pharmacology
Head-to-head clinical analysis: FLUPHENAZINE HYDROCHLORIDE versus PROCHLORPERAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUPHENAZINE HYDROCHLORIDE versus PROCHLORPERAZINE.
FLUPHENAZINE HYDROCHLORIDE vs PROCHLORPERAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system; also exhibits anticholinergic, alpha-adrenergic blocking, and extrapyramidal effects.
Prochlorperazine is a phenothiazine antipsychotic that acts as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone (CTZ) and at high doses in the mesolimbic system. It also has anticholinergic and antiemetic effects.
2.5-10 mg orally divided every 6-8 hours initially; maintenance 1-5 mg orally daily. For severe psychoses, 2.5-10 mg intramuscularly every 6-8 hours. Maximum oral dose 40 mg/day.
5-10 mg IM/IV every 3-4 hours as needed; or 5-10 mg PO 3-4 times daily; or 25 mg PR twice daily. Maximum IM/IV: 40 mg/day; PO: 40 mg/day.
None Documented
None Documented
Clinical Note
moderateProchlorperazine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluticasone propionate."
Clinical Note
moderateProchlorperazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Prochlorperazine."
Clinical Note
moderateProchlorperazine + Methylphenidate
"The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate."
Clinical Note
moderateTerminal elimination half-life 14-24 hours after oral administration; may be longer (up to 48 hours) with chronic use due to accumulation in deep tissues. Clinically, steady state is achieved in 4-7 days.
Terminal elimination half-life: 23-25 hours, with prolonged elimination in hepatic impairment.
Primarily renal (approximately 50-60% as metabolites, <1% unchanged); fecal (30-40% via biliary elimination); small amount excreted in breast milk.
Renal: 70-80% (as metabolites), Fecal: 20-30% (unchanged and metabolites), Biliary: 10-15% of dose excreted in bile.
Category A/B
Category A/B
Typical Antipsychotic
Typical Antipsychotic / Antiemetic
Prochlorperazine + Quinagolide
"The therapeutic efficacy of Quinagolide can be decreased when used in combination with Prochlorperazine."